Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 27 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Marksans Pharma Ltd

About the Company - Marksans Pharma Ltd

Marksans Pharma Ltd. is a Public Limited Listed company incorporated on 16/04/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1992PLC066364 and registration number is 066364. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 658.29 Cr. and Equity Capital is Rs. 40.93 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals11th Floor, Grandeur, Veera Desai Extension Road, Mumbai Maharashtra 400053companysecretary@marksanspharma.com
http://www.marksanspharma.com
Management
NamePosition Held
Mr. Mark SaldanhaChairman & Managing Director
Mrs. Sandra SaldanhaWhole Time Director
Mr. Seetharama R BuddharajuIndependent Director
Mr. Abhinna Sundar MohantyIndependent Director
Mr. Digant Mahesh ParikhIndependent Director
Mr. Varddhman V JainWhole Time Director
Mrs. Shailaja VardhanIndependent Director
Dr. Sunny SharmaNon Executive Director

Marksans Pharma Ltd. Share Price Update

Share PriceValue
Today₹159.80
Previous Day₹158.25

Basic Stock Data of Marksans Pharma Ltd

Market Cap 7,137 Cr.
Current Price 158
High / Low179/64.3
Stock P/E22.5
Book Value 41.4
Dividend Yield0.32 %
ROCE22.2 %
ROE18.6 %
Face Value 1.00

Data Source: screener.in

Competitors of Marksans Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
J B Chemicals & Pharmaceuticals Ltd 25,542 Cr. 1,6461,940/87549.7 1750.54 %22.4 %17.6 % 1.00
Panacea Biotec Ltd 987 Cr. 161202/107 1380.00 %10.3 %10.9 % 1.00
Sequent Scientific Ltd 3,483 Cr. 140156/61.8 25.30.00 %3.43 %8.98 % 2.00
Wockhardt Ltd 8,192 Cr. 568595/145 2170.00 %0.46 %8.31 % 5.00
Pfizer Ltd 20,398 Cr. 4,4594,840/3,40740.2 7150.78 %26.2 %19.8 % 10.0
Industry Average11,720.40 Cr1,394.8017.98254.060.26%12.56%13.12%3.80

Marksans Pharma Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales356358330349361363418434453480486500531
Expenses273267235272301305354361372403376398417
Operating Profit83919577605864738077110102114
OPM %23%25%29%22%17%16%15%17%18%16%23%20%21%
Other Income4-36691215161418111019
Interest2231215232222
Depreciation199177921111413141418
Profit before tax6678977560605376787910497114
Tax %23%24%18%16%23%20%44%21%23%21%21%27%26%
Net Profit51598063464830606062837084
EPS in Rs1.241.441.941.531.111.180.691.461.511.571.811.521.84

Marksans Pharma Ltd Quarterly Chart

Marksans Pharma Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales3564386307978937679131,0001,1341,3761,4911,8522,103
Expenses4553695126127577228348689421,0371,2321,5131,645
Operating Profit-100691181851364578132192340259340458
OPM %-28%16%19%23%15%6%9%13%17%25%17%18%22%
Other Income2443978507425945
Interest54151916107101098899
Depreciation24161616283027232736455267
Profit before tax-17544861561071550104157302248338427
Tax %-1%-12%15%28%23%24%28%23%23%21%25%21%
Net Profit-176497411283113680121239187265320
EPS in Rs1.191.872.671.920.220.801.872.955.834.515.887.01
Dividend Payout %-0%10%5%4%21%23%6%3%3%4%6%9%

Marksans Pharma Ltd Profit & Loss Yearly Chart

Marksans Pharma Ltd Growth

Compounded Sales Growth
10 Years:16%
5 Years:15%
3 Years:18%
TTM:20%
Compounded Profit Growth
10 Years:19%
5 Years:52%
3 Years:30%
TTM:51%
Stock Price CAGR
10 Years:24%
5 Years:43%
3 Years:35%
1 Year:143%
Return on Equity
10 Years:20%
5 Years:21%
3 Years:22%
Last Year:19%

Marksans Pharma Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital37393941414141414141414545
Reserves-22034903264013924305025958461,0681,7001,830
Preference Capital14141412120000000
Borrowings17916316089881101181003034111123111
Other Liabilities389165202220192209142160236307416322327
Total Liabilities3854014906767227527318029021,2281,6362,1902,314
Fixed Assets165156146166270267279270303309428486560
CWIP0000000001231019
Investments0000000000011
Other Assets2202453445104524844515335999071,2051,6941,734
Total Assets3854014906767227527318029021,2281,6362,1902,314

Marksans Pharma Ltd Reserves and Borrowings Chart

Marksans Pharma Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity -6239651553114502723317999237
Cash from Investing Activity -3-5-4-33-123-21-39-13-60-45-42-259
Cash from Financing Activity 57-40-2917-58-33-21-114-1580198
Net Cash Flow-9-731138-150-1015-760119137176

Marksans Pharma Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days116109988489118716478729782
Inventory Days126112102107120151152215155248216192
Days Payable1008183888512954787110310291
Cash Conversion Cycle141141118103124140169202163217211183
Working Capital Days-2183748559513011713394110138133
ROCE %-277%43%37%44%23%4%10%18%25%38%23%22%

Marksans Pharma Ltd Financial Efficiency Indicators Chart

Marksans Pharma Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters48.25%48.25%48.25%48.25%48.25%48.25%48.25%48.60%49.00%43.85%43.85%43.85%
FIIs5.05%4.34%3.14%2.64%2.59%3.46%4.04%4.06%4.23%15.11%14.90%15.07%
DIIs0.30%0.34%0.56%0.53%0.41%0.47%0.94%0.95%0.96%1.46%3.65%4.02%
Public46.40%47.07%48.05%48.58%48.75%47.82%46.77%46.38%45.79%39.57%37.60%37.06%
No. of Shareholders1,30,1161,35,2711,88,8882,01,4512,14,9982,20,0902,21,3592,17,7432,13,1231,98,3821,88,4472,07,937

Marksans Pharma Ltd Shareholding Pattern Chart

No. of Marksans Pharma Ltd Shareholders

Marksans Pharma Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Quant Small Cap Fund126412591.88210.29
UTI Aggressive Hybrid Fund20782530.4621.94
UTI Large & Mid Cap Fund10826110.5811.43
UTI Retirement Fund10494990.2811.08
Motilal Oswal Nifty Microcap 250 Index Fund2257770.663.76
UTI Healthcare Fund2327110.322.46
Motilal Oswal S&P BSE Healthcare ETF26910.490.04
Groww Nifty Total Market Index Fund5570.020.01

Marksans Pharma Ltd ROCE Trend

Marksans Pharma Ltd EPS Trend

Marksans Pharma Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)6.414.515.762.861.87
Diluted EPS (Rs.)6.414.515.762.861.87
Cash EPS (Rs.)7.005.666.713.602.52
Book Value[Excl.RevalReserv]/Share (Rs.)38.9529.8822.1215.8613.50
Book Value[Incl.RevalReserv]/Share (Rs.)38.9529.8822.1215.8613.50
Revenue From Operations / Share (Rs.)40.8736.4233.6227.7124.43
PBDIT / Share (Rs.)8.807.358.464.703.34
PBIT / Share (Rs.)7.656.257.584.052.78
PBT / Share (Rs.)7.456.057.383.842.55
Net Profit / Share (Rs.)5.854.565.832.951.97
NP After MI And SOA / Share (Rs.)5.884.565.832.951.97
PBDIT Margin (%)21.5220.1725.1616.9713.67
PBIT Margin (%)18.7217.1622.5314.6211.39
PBT Margin (%)18.2316.6021.9513.8510.42
Net Profit Margin (%)14.3212.5317.3310.648.04
NP After MI And SOA Margin (%)14.3712.5317.3310.648.04
Return on Networth / Equity (%)15.2515.5326.9018.9814.82
Return on Capital Employeed (%)18.7519.9333.3524.6219.95
Return On Assets (%)12.1511.3919.4213.3710.00
Total Debt / Equity (X)0.020.030.020.020.18
Asset Turnover Ratio (%)0.430.600.730.610.63
Current Ratio (X)4.913.373.022.592.28
Quick Ratio (X)3.492.181.671.541.02
Inventory Turnover Ratio (X)1.221.291.741.141.44
Dividend Payout Ratio (NP) (%)3.815.471.7124.435.52
Dividend Payout Ratio (CP) (%)3.194.411.4920.014.30
Earning Retention Ratio (%)96.1994.5398.2975.5794.48
Cash Earning Retention Ratio (%)96.8195.5998.5179.9995.70
Interest Coverage Ratio (X)43.6735.6143.3622.0214.16
Interest Coverage Ratio (Post Tax) (X)30.0723.1230.8714.819.33
Enterprise Value (Cr.)2540.861577.141869.83507.171103.73
EV / Net Operating Revenue (X)1.371.061.360.441.10
EV / EBITDA (X)6.375.245.402.638.07
MarketCap / Net Operating Revenue (X)1.721.251.490.501.02
Retention Ratios (%)96.1894.5298.2875.5694.47
Price / BV (X)1.831.552.310.891.87
Price / Net Operating Revenue (X)1.721.251.490.501.02
EarningsYield0.080.100.110.210.07

Marksans Pharma Ltd Profitability Ratios (%)

Marksans Pharma Ltd Liquidity Ratios

Marksans Pharma Ltd Liquidity Ratios (%)

Marksans Pharma Ltd Interest Coverage Ratios (%)

Marksans Pharma Ltd Valuation Ratios

Fair Value of Marksans Pharma Ltd Stock

Fair Value: ₹173.81

The stock is undervalued by 10.01% compared to the current price ₹158

*Investments are subject to market risks

Strength and Weakness of Marksans Pharma Ltd Stock

StrengthWeakness
  1. The company has higher reserves (614.92 cr) compared to borrowings (5.08 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (369.31 cr) and profit (143.00 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 5.66 and average Dividend Yield of 16.88%.
  2. The stock has a low average ROCE of 0.83%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 72.67, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 159.33, which may not be favorable.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Marksans Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE